Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 23, 2021

Primary Completion Date

October 21, 2021

Study Completion Date

January 6, 2022

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG

Abiraterone Acetate Tablets (I)

DRUG

ZYTIGA®

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY